Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: For use in clinical practice to inform research

Pediatric Rheumatology

Volumn 12, Issue 1, 2014, Pages

  McCann, Liza J ^a   Arnold, Katie ^b   Pilkington, Clarissa A ^b,d   Huber, Adam M ^e   Ravelli, Angelo ^f   Beard, Laura ^b   Beresford, Michael W ^a,g   Wedderburn, Lucy R ^b,c,d  

^a ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e IWK HEALTH CENTRE   (Canada)

^f UNIVERSITY OF GENOA   (Italy)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Collaboration; Core set; Dataset; Disease activity; Idiopathic Inflammatory myopathy; International; Juvenile dermatomyositis

Indexed keywords

BIOLOGICAL MARKER;

CANADA; CHILD; CLASSIFICATION; DERMATOMYOSITIS; DISEASE COURSE; DISEASE MANAGEMENT; FEMALE; HUMAN; INTERNATIONAL COOPERATION; IRELAND; ITALY; MALE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT ACUITY; UNITED KINGDOM;

BIOLOGICAL MARKERS; CANADA; CHILD; DERMATOMYOSITIS; DISEASE MANAGEMENT; DISEASE PROGRESSION; FEMALE; GREAT BRITAIN; HUMANS; INTERNATIONAL COOPERATION; IRELAND; ITALY; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT ACUITY;

EID: 84904445897     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-12-31     Document Type: Article

References (37)

1. Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, Maillard S, Oliveira SK, Sztajnbok F, Cuttica R, Beltramelli M, Corona F, Katsicas MM, Russo R, Ferriani V, Burgos-Vargas R, Magni-Manzoni S, Solis-Valleoj E, Bandeira M, Zullian F, Baca V, Cortis E, Falcini F, Alessio M, Alpigiani MG, Gerloni V, Saad-Magalhaes C, Podda R, Silva CA, Lepore L, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 2010, 62:63-72.
2. Mathiesen PR, Zak M, Herlin T, Nielsen SM. Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. Clin Exp Rheumatol 2010, 28:782-789.
3. Sanner H, Kirkhus E, Merckoll E, Tollisen A, Roisland M, Lie BA, Taraldsrud E, Gran JT, Flato B. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case-control study. Arthritis Care Res (Hoboken) 2010, 62:1103-1111.
4. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008, 371:2201-2212.
5. Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 2011, 7:664-675.
6. Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 1995, 34:732-736.
7. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, Pachman LM. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003, 49:300-305.
8. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE, . RIM Study Group Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013, 65:314-324. RIM Study Group.
9. Ruperto N, Pistorio A, Oliveira S, Cuttica RJ, Ravelli A, Fischbach M, Hagelberg S, Avcin A, Cheuret E, Corona F, Couillault G, Dressler F, Gerloni V, Sterba G, Zulian F, Apaz MT, Cespedes-Cruz A, Cimaz R, Bracaglia C, Joos R, Quartier P, Russo R, Tardieu M, Wulfraat N, Angioloni S, Martini A. A randomised trial in new onset juvenile dermatomyositis: prednisolone versus prednisolone plus cyclosporine verus prednisolone plus methotrexate. [abstract]. Arthritis Rheum 2012, 64:2473.
10. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, Lachenbruch PA, Miller FW. Defining Clinical Improvement in Adult and Juvenile Myositis. J Rheumatol 2003, 30:603-617.
11. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, Lachenbruch PA, Miller FW. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004, 50:2281-2290.
12. Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, Feldman BM, Giannini EH, Miller FW. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005, 52:2607-2615.
13. Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, Brunner J, Dannecker G, Silva CA, Stanevicha V, Cate RT, van Suijlekom-Smit LW, Voygioyka O, Fischbach M, Foeldvari I, Hilario O, Modesto C, Saurenmann RK, Sauvain MJ, Scheibel I, Sommelet D, Tambic-Bukovac L, Barcellona R, Brik R, Ehl S, Jovanovic M, Rovensky J, Bagnasco F, Lovell DJ, Martini A, et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008, 59:4-13.
14. Ruperto N, Pistorio A, Ravelli A, Rider LG, Pilkington C, Oliveira S, Wulffraat N, Espada G, Garay S, Cuttica R, Hofer M, Quartier P, Melo-Gomes J, Reed AM, Wierzbowska M, Feldman BM, Harjacek M, Huppertz HI, Nielsen S, Flato B, Lahdenne P, Michels H, Murray KJ, Punaro L, Rennebohm R, Russo R, Balogh Z, Rooney M, Pachman LM, Wallace C, et al. The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010, 62:1533-1541.
15. Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, Garay S, Kuis W, Machado C, Pachman L, Prieur AM, Rider LG, Silverman E, Tsitsami E, Woo P, Giannini EH, Martini A, . Paediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG) Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 2003, 42:1452-1459. Paediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG).
16. Lundberg IE, Svensson J. Registries in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2013, 25:729-734.
17. Lionetti G, Kimura Y, Schanberg LE, Beukelman T, Wallace CA, Ilowite NT, Winsor J, Fox K, Natter M, Sundy JS, Brodsky E, Curtis JR, Del Gaizo V, Iyasu S, Jahreis A, Meeker-O'Connell A, Mittleman BB, Murphy BM, Peterson ED, Raymond SC, Setoguchi S, Siegel JN, Sobel RE, Solomon D, Southwood TR, Vesely R, White PH, Wulffraat NM, Sandborg CI. Using registries to identify adverse events in rheumatic diseases. Pediatrics 2013, 132:e1384-e1394.
18. Martin N, Krol P, Smith S, Murray K, Pilkington CA, Davidson JE, Wedderburn LR. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology (Oxford) 2011, 50:137-145.
19. Natter MD, Quan J, Ortiz DM, Bousvaros A, Ilowite NT, Inman CJ, Marsolo K, McMurry AJ, Sandborg CI, Schanberg LE, Wallace CA, Warren RW, Weber GM, Mandl KD. An i2b2-based, generalizable, open source, self-scaling chronic disease registry. J Am Med Inform Assoc 2013, 20:172-179.
20. Robinson AB, Hoeltzel MF, Wahezi DM, Becker ML, Kessler E, Schmeling H, Carrasco R, Huber AM, Feldman BM, Reed AM. Clinical characteristics of children with juvenile dermatomyositis - the children's arthritis and rheumatology research alliance (CARRA) registry. Arthritis Care Res (Hoboken) 2013, doi:10.1002/acr.22142[Epub ahead of print].
21. McCann LJPCA, Beard L, Ravelli A, Huber A, Wedderburn LR. Proposal for the development of an international minimal data collection for juvenile dermatomyositis [abstract]. Arthritis Rheum 2011, 61:234.
22. Dugan EM, Huber AM, Miller FW, Rider LG. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J 2009, 15:1.
23. Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken) 2011, 63(Suppl 11):S118-S157.
24. Wedderburn LR, McHugh NJ, Chinoy H, Cooper RG, Salway F, Ollier WE, McCann LJ, Varsani H, Dunphy J, North J, Davidson JE. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 2007, 46:1786-1791.
25. Tansley SL, McHugh NJ, Wedderburn LR. Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?. Arthritis Res Ther 2013, 15:211.
26. Alemo Munters L, van Vollenhoven RF, Alexanderson H. Patient preference assessment reveals disease aspects not covered by recommended outcomes in polymyositis and dermatomyositis. ISRN Rheumatol 2011, 2011:463124.
27. Filocamo G, Consolaro A, Ferrari C, Ravelli A. Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress. Clin Exp Rheumatol 2013, 31:964-968.
28. Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, Pachman LM, Pilkington C, Reed AM, Rennebohm LG, Rider RM, Wallace CA, Feldman BA. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken) 2010, 62:219-225.
29. Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, Wulffraat NM, Malattia C, Garay SM, Hofer M, Quartier P, Dolezalova P, Penades IC, Ferriani VP, Ganser G, Kasapcopur O, Melo-Gomes JA, Reed AM, Wierzbowska M, Rider LG, Martini A, Ruperto N, . Paediatric Rheumatology International Trials Organisation (PRINTO) The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis 2013, 72:686-693. Paediatric Rheumatology International Trials Organisation (PRINTO).
30. Wulffraat NM, Vastert B. Time to share. Pediatr Rheumatol Online J 2013, 11:5.
31. Bohan A, Peter JB. Polymyositis and dermatomyositis. Parts 1 and 2. New Engl J Med 1975, 292:344-347. 403-407.
32. Washington Neuromuscular Disease Centre [http://neuromuscular.wustl.edu].
33. Santmyire-Rosenberger B, Dugan EM. Skin Involvement in Dermatomyositis. Curr Opin Rheumatol 2003, 15:714-722.
34. Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, Hicks JE, Levinson JE, Mier R, Pachman LM, Passo MH, Perez MD, Reed AM, Schikler KN, Smith M, Zemel LS, Rider LG. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: II. The childhood myositis assessment scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999, 42:2213-2219.
35. Huber AM, Lovell DJ, Pilkington CA, Rennebohm RM, Rider LG. Confusion concerning multiple versions of the Childhood Myositis Assessment Scale. Arthritis Care Res 2013, doi:10.1002/acr.22239[Epub ahead of print].
36. Nugent J, Ruperto N, Grainger J, Machado C, Sawhney S, Baildam E, Davidson J, Foster H, Hall A, Hollingworth P, Sills J, Venning H, Walsh JE, Landgraf JM, Roland M, Woo P, Murray KJ, . Paediatric Rheumatology International Trials Organisation The British version of the Childhood Health assessment questionnaire (CHAQ) and the child health Questionnaire (CHQ). Clin Exp Rheumatol 2001, 2001(19):S163-S167. Paediatric Rheumatology International Trials Organisation.
37. Huber AM, Hicks JE, Lachenbruch PA, Perez MD, Zemel LS, Rennebohm RM, Wallace CA, Lindsley CB, Passo MH, Ballinger SH, Bowyer SL, Reed AM, White PH, Katona IM, Miller FW, Rider LG, Feldman BM, . Juvenile Dermatomyositis Disease Activity Collaborative Group Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol 2001, 28:1106-1111. Juvenile Dermatomyositis Disease Activity Collaborative Group.